cas 439280-18-9|| where to buy 3-fluoro-5-methoxybenzonitrile

Nom du produit:3-fluoro-5-methoxybenzonitrile

IUPAC Name:3-fluoro-5-methoxybenzonitrile

Unité d'emballage	Stock disponible	Prix($)	Quantité
CM160225-25g	in stock	ŸŸ

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 439280-18-9 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:439280-18-9; Formule moléculaire:C8H6FNO; Point de fusion:-; Code SMILES:COC1=CC(=CC(F)=C1)C#N; Densité:

: Numéro de catalogue:CM160225; Poids moléculaire:151.14; Point d'ébullition:203.5°C at 760 mmHg; N° Mdl:MFCD06797883; Stockage:Store at room temperature.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Belzutifan; On September 19, MSD announced that the U.S. FDA has accepted and granted priority review for a supplemental new drug application (sNDA) seeking approval for Welireg (Belzutifan), Merck's oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for the treatment of adult patients with advanced renal cell carcinoma (RCC). Welireg was the first HIF-2α inhibitor therapy approved in the U.S. and is currently approved for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated RCC, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, not requiring immediate surgery.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.